^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Abbott

    i
    Other names: Abbott | KOS Pharma | Facet Biotech | Solvay | Ravizza Farmaceutici | CFR Pharma | Primal Healthcare | Alere Inc | St Jude Medical | Laboratorio Franco Colombiano Lafrancol | Lafrancol | Cytec | Veropharm | Laboratorios Recalcine | Fournier Pharma | Kos Pharmaceuticals | Kos Pharmaceuticals, | Facet Biotech Corporation | Facet Biotech Corp | Solvay S.A. | Solvay SA | Solvay S A | Ravizza Farmaceutici SpA | CFR Pharmaceuticals | Piramal Healthcare Ltd | Alere Inc. | Alere, Inc. | Alere, LLC | Alere LLC | St. Jude Medical, Inc. | Laboratorio Franco-Colombiano S.A.S. | Laboratorios Lafrancol | Fournier Pharma Inc. | Fournier Industrie et Sante SAS | Fournier Pharma Corp | Alere | Piramal Healthcare | Walk Vascular | Thoratec | Cephea Valve Technologies | Evalve Corporation | Evalve, Inc. | Ibis Biosciences | Endosense | Biosite | CardioMEMS | Cholestech | EP MedSystems | IDEV Technologies | Inverness Medical Innovations | Irvine Biomedical | Nanostim | NeuroTherm | Ostex International | Spinal Modulation, | Spinal Modulation | Tendyne Holdings | Therasense | Ventritex | Knoll Pharmaceuticals
    Related tests:
    Evidence

    News

    over1year
    Abbott receives FDA approval for HPV test to run on Alinity m, offering primary HPV screening and assessment of high-risk cancer-causing types of HPV (PRNewswire)
    "Abbott...has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays...The Alinity m high risk (HR) HPV assay is approved as a test for HPV detection and for use in routine cervical cancer screening as per professional medical guidelines."
    FDA event
    |
    ALINITY m HR HPV ASSAY
    over1year
    FDA approves new therapy for rare form of blood cancers called myelodysplastic syndromes (FDA)
    "...U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime IDH1 Assay as a companion diagnostic for the selection of R/R MDS patients with an IDH1 mutation."
    FDA event
    |
    Abbott RealTime IDH1
    over2years
    FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation (FDA)
    "...Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test...FDA also approved the Abbott RealTime IDH1 Assay to select patients for olutasidenib."
    FDA event
    |
    Abbott RealTime IDH1